MCID: HNS001
MIFTS: 32

Hansen's Disease

Categories: Rare diseases

Aliases & Classifications for Hansen's Disease

MalaCards integrated aliases for Hansen's Disease:

Name: Hansen's Disease 20 3
Leprosy 20 70

Classifications:



External Ids:

UMLS 70 C0023343

Summaries for Hansen's Disease

GARD : 20 Hansen's disease (also known as leprosy) is a rare bacterial infection that affects the skin, nerves and mucous membranes. After exposure, it may take anywhere from 2 to 10 years to develop features of the condition. Once present, common signs and symptoms include skin lesions ; muscle weakness or paralysis; eye problems that may lead to blindness; nosebleeds; severe pain; and/or numbness in the hands, feet, arms and legs. Hansen's disease is caused by the bacterium Mycobacterium leprae; however, the way in which the bacterium is transmitted (spread) is poorly understood. It appears that only about 5% of people are susceptible to the condition. Hansen's disease is easily treated with combination antibiotics for 6 months to 2 years.

MalaCards based summary : Hansen's Disease, also known as leprosy, is related to leprosy 1 and leprosy 3. An important gene associated with Hansen's Disease is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2). The drugs Clofazimine and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include eye, t cells and skin.

CDC : 3 Hansen's disease (also known as leprosy) is an infection caused by slow-growing bacteria called Mycobacterium leprae. It can affect the nerves, skin, eyes, and lining of the nose (nasal mucosa). With early diagnosis and treatment, the disease can be cured. People with Hansen's disease can continue to work and lead an active life during and after treatment. Leprosy was once feared as a highly contagious and devastating disease, but now we know it doesn't spread easily and treatment is very effective. However, if left untreated, the nerve damage can result in crippling of hands and feet, paralysis, and blindness.

Related Diseases for Hansen's Disease

Diseases related to Hansen's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 781)
# Related Disease Score Top Affiliating Genes
1 leprosy 1 11.6
2 leprosy 3 11.5
3 leprosy 5 11.4
4 leprosy 2 11.4
5 leprosy 4 11.3
6 trigeminal trophic syndrome 11.0
7 mycobacterium abscessus 11.0
8 buruli ulcer 10.9
9 mycobacterium kansasii 10.9
10 chronic rhinitis 10.9
11 fetal thalidomide syndrome 10.9
12 lepromatous leprosy 10.6
13 erythema nodosum 10.5
14 allergic disease 10.5
15 neuropathy 10.4
16 peripheral nervous system disease 10.4
17 tuberculoid leprosy 10.3
18 neuritis 10.3
19 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
20 pustulosis of palm and sole 10.3
21 psoriasis 10.3
22 disease by infectious agent 10.3
23 glomerulonephritis 10.2
24 tetanus 10.2
25 ectropion 10.2
26 scabies 10.2
27 lupus erythematosus 10.2
28 dermatitis 10.2
29 exanthem 10.2
30 uveitis 10.2
31 pulmonary tuberculosis 10.2
32 systemic lupus erythematosus 10.2
33 antiphospholipid syndrome 10.2
34 mycosis fungoides 10.1
35 yaws 10.1
36 leprosy 6 10.1
37 borderline leprosy 10.1
38 skin disease 10.1
39 dysautonomia 10.1
40 autoimmune disease 10.1
41 infant gynecomastia 10.1
42 filarial elephantiasis 10.1
43 gynecomastia 10.1
44 visceral leishmaniasis 10.1
45 47,xyy 10.1
46 onchocerciasis 10.1
47 tenosynovitis 10.1
48 autonomic dysfunction 10.1
49 yemenite deaf-blind hypopigmentation syndrome 10.1
50 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1

Graphical network of the top 20 diseases related to Hansen's Disease:



Diseases related to Hansen's Disease

Symptoms & Phenotypes for Hansen's Disease

Drugs & Therapeutics for Hansen's Disease

Drugs for Hansen's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clofazimine Approved, Investigational Phase 4 2030-63-9 2794
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
4
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
5 Vitamins Phase 4
6 Vitamin B9 Phase 4
7 Folic Acid Antagonists Phase 4
8 Antiparasitic Agents Phase 4
9 Vitamin B Complex Phase 4
10 Folate Phase 4
11 Antiprotozoal Agents Phase 4
12 Antimalarials Phase 4
13
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
14
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
15
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
16
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
17
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
18
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
19
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
20
Rifampicin Approved Phase 3 13292-46-1 5458213 5381226
21
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
22
Amitriptyline Approved Phase 3 50-48-6 2160
23
Perphenazine Approved Phase 3 58-39-9 4748
24
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
25
Moxifloxacin Approved, Investigational Phase 2, Phase 3 151096-09-2, 354812-41-2 152946
26
Linezolid Approved, Investigational Phase 2, Phase 3 165800-03-3 441401
27
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
28 Hormone Antagonists Phase 2, Phase 3
29 Hormones Phase 2, Phase 3
30 Immunosuppressive Agents Phase 2, Phase 3
31 Methylprednisolone Acetate Phase 2, Phase 3
32 Antirheumatic Agents Phase 2, Phase 3
33 Cyclosporins Phase 2, Phase 3
34 Antifungal Agents Phase 2, Phase 3
35 glucocorticoids Phase 2, Phase 3
36 Antineoplastic Agents, Hormonal Phase 2, Phase 3
37 Calcineurin Inhibitors Phase 2, Phase 3
38 Immunologic Factors Phase 2, Phase 3
39 Dermatologic Agents Phase 2, Phase 3
40 Antitubercular Agents Phase 3
41 Neurotransmitter Agents Phase 3
42 Antibiotics, Antitubercular Phase 3
43 Psychotropic Drugs Phase 3
44 Amitriptyline, perphenazine drug combination Phase 3
45 Narcotics Phase 3
46 Analgesics Phase 3
47 Antidepressive Agents, Tricyclic Phase 3
48 Adrenergic Agents Phase 3
49 Analgesics, Opioid Phase 3
50 Antipsychotic Agents Phase 3

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Effect of Additional Clofazimine on ENL Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
3 Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
4 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
5 A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
6 Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Recruiting NCT03942354 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Directly observed therapy (DOT)
7 Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) Recruiting NCT04081077 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine
8 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Recruiting NCT03662022 Phase 3 Rifampicin
9 Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study Recruiting NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
10 Economic Evaluation of New MDR TB Regimens (PRACTECAL EE) Not yet recruiting NCT04207112 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Standard Drugs
11 Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region Completed NCT00128193 Phase 2
12 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
13 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
14 A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone. Completed NCT00919451 Phase 2 ciclosporin
15 An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
16 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
17 The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study Withdrawn NCT01885611 Phase 1, Phase 2
18 A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy Withdrawn NCT03947437 Phase 1, Phase 2
19 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
20 Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients Completed NCT01006759 Phase 1
21 Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Completed NCT01920750 Phase 1
22 A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects Completed NCT03302897 Phase 1
23 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
24 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
25 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Unknown status NCT03683745
26 Molecular Epidemiology of Leprosy in Colombia Completed NCT00138437
27 Observation of Microcirculation Impairment in Patients With Lepromatous Leprosy Using Orthogonal Polarization Spectral (OPS) Imaging and Laser Doppler Iontophoresis Completed NCT02085317 acetylcholine Iontophoresis;sodium nitroprusside Iontophoresis
28 Educational Virtual Objects (The Virtual Human Project) Assessment Inserted in Learning Based on Team (Team-based Learning) in Leprosy Education on Undergraduate Medical Setting Completed NCT02484469
29 Small Membrane Filtration (SMF) Method to Improve the Performance of Smear Microscopy for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting Completed NCT02701439
30 Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial Completed NCT00860717
31 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
32 Improved Understanding of Ongoing Transmission of Leprosy in the Comoros, a Region Hyperendemic for the Disease. Recruiting NCT03526718
33 Clofazamine in the Long Term Treatment of Leprosy, Phase III No longer available NCT00852345 clofazamine
34 Prospective Randomized Controlled Trial Comparing Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer. Terminated NCT01751503
35 CD8 Reactivity to Microorganisms in Blood and Breast Milk Terminated NCT03084614

Search NIH Clinical Center for Hansen's Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Thalidomide

Genetic Tests for Hansen's Disease

Anatomical Context for Hansen's Disease

MalaCards organs/tissues related to Hansen's Disease:

40
Eye, T Cells, Skin, Monocytes, Bone Marrow, Bone, Myeloid

Publications for Hansen's Disease

Articles related to Hansen's Disease:

(show top 50) (show all 21401)
# Title Authors PMID Year
1
Thalidomide affects limb formation and multiple myeloma related genes in human induced pluripotent stem cells and their mesoderm differentiation. 61
33763605 2021
2
Tectona grandis leaf extract ameliorates hepatic fibrosis: Modulation of TGF- β /Smad signaling pathway and upregulating MMP3/TIMP1 ratio. 61
33610708 2021
3
Sonographic evaluation of leprosy of ulnar nerve. 61
33680276 2021
4
Dapsone-induced hepatic complications: it's time to think beyond methemoglobinemia. 61
31631707 2021
5
Morphometric analysis of nerve fibers in neural leprosy. 61
33347629 2021
6
Drug resistance to rifampicin in a case of steroid-dependent erythema nodosum leprosum and the therapeutic implications of resistance and reactions in leprosy. 61
33811328 2021
7
Strengthening individual and family resilience against leprosy-related discrimination: A pilot intervention study. 61
33798199 2021
8
[Aleijadinho : Leprosy and the sculptor Antonio Francisco Lisboa in 18th century Brazil]. 61
33044560 2021
9
Leprosy post-exposure prophylaxis risks not adequately assessed. 61
33740405 2021
10
Leprosy post-exposure prophylaxis risks not adequately assessed - Author's reply. 61
33740406 2021
11
Hansen's disease in the era of COVID-19: An observation on a series of six patients with co-infection. 61
33527634 2021
12
The first probable evidence of leprosy in a male individual (17th-19th century AD) unearthed in Northern Portugal (Travanca, Santa Maria da Feira). 61
33482498 2021
13
The long-term impact of the Leprosy Post-Exposure Prophylaxis (LPEP) program on leprosy incidence: A modelling study. 61
33788863 2021
14
The Clinical Trend of Leprosy from 2000 to 2016 in Kaohsiung, a Major International Harbor City in Taiwan, Where Leprosy is Almost Eradicated. 61
32863349 2021
15
Improving treatment outcomes for leprosy in Pernambuco, Brazil: a qualitative study exploring the experiences and perceptions of retreatment patients and their carers. 61
33740912 2021
16
Physical disabilities caused by leprosy in 100 million cohort in Brazil. 61
33752632 2021
17
[Lepers & leprosy in Jerusalem in the 19th & 20th centuries The establishment of the German Leper homes 1867-1918]. 61
33749187 2021
18
Geospatial epidemiology of leprosy in northwest Bangladesh: a 20-year retrospective observational study. 61
33752751 2021
19
Leprosy in Nepal: a re-emerging threat. 61
33093588 2021
20
Histoid Leprosy: An Enemy Not Yet Eradicated. 61
32997963 2021
21
Social inequalities and their association with the leprosy burden in a Brazilian city of low endemicity: An ecological study. 61
33676938 2021
22
Susceptibility and resistance in leprosy: Studies in the mouse model. 61
33660297 2021
23
High-resolution ultrasound in the assessment of peripheral nerves in leprosy: A comparative cross-sectional study. 61
33769731 2021
24
"Pearls and Oy-sters "Quiet Nerve Paralysis" due to Symmetrical Neuropathy in Pure Neuritic Leprosy. 61
33762422 2021
25
Revised estimates of leprosy disability weights for assessing the global burden of disease: A systematic review and individual patient data meta-analysis. 61
33651814 2021
26
Mapping leprosy-associated coding variants of interleukin genes by targeted sequencing. 61
33646620 2021
27
Misdiagnosis of leprosy in Brazil in the period 2003 - 2017: spatial pattern and associated factors. 61
33310076 2021
28
In search of biomarkers for leprosy by unraveling the host immune response to Mycobacterium leprae. 61
33709405 2021
29
Towards the elimination of leprosy in Yunnan, China: A time-series analysis of surveillance data. 61
33725010 2021
30
Increased oxidative stress in elderly leprosy patients is related to age but not to bacillary load. 61
33690671 2021
31
Adverse effects of polychemotherapy for leprosy in 13 years of follow-up at a university hospital. 61
33637399 2021
32
A new diagnostic sampling method in pure neural leprosy: the scraping of the myelin sheath. 61
33781645 2021
33
Unusual non-trophic ulcerations in leprosy: A case series of 17 patients. 61
33722150 2021
34
Study of TNF-α, IFN-γ, TGF-β, IL-6, and IL-10 Gene Polymorphism in Individuals from the Leprosy-Endemic Area in the Brazilian Amazon. 61
33656915 2021
35
Cytology in the diagnosis of concomitant tuberculosis and leprosy by polymerase chain reaction using cytology scrapings. 61
32609905 2021
36
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. 61
33727703 2021
37
Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes. 61
32914207 2021
38
Use of Customized Bacteriophages in the Treatment of Chronic Nonhealing Wounds: A Prospective Study. 61
31752578 2021
39
Ethnopharmacology, biological activity and phytochemistry of Scaevola spinescens R. Br. 61
33719150 2021
40
Cutaneous tuberculosis of the pinna. 61
33251595 2021
41
Reconstructive surgery for sequellae of Mycobacterium ulcerans infection (Buruli ulcer) of the upper limb. 61
33645421 2021
42
Strategies for drug target identification in Mycobacterium leprae. 61
33798649 2021
43
Gmelina arborea- an indigenous timber species of India with high medicinal value: A review on its pharmacology, pharmacognosy and phytochemistry. 61
33217516 2021
44
Development of a novel loop-mediated isothermal amplification assay for rapid detection of Mycobacterium leprae in clinical samples. 61
33666034 2021
45
Increased serum levels of interleukin-6 in erythema nodosum leprosum suggest its use as a biomarker. 61
33769734 2021
46
Cyclooxygenase 2 and vascular endothelial growth factor-potential targets to manage lepra reactions: A case-control study. 61
33594711 2021
47
Evaluating the health effect of a Social Housing programme, Minha Casa Minha Vida, using the 100 million Brazilian Cohort: a natural experiment study protocol. 61
33649053 2021
48
Zoonotic risk of Hansen's disease from community contact with wild armadillos: A systematic review and meta-analysis. 61
33226194 2021
49
Mycobacterium leprae-helminth co-infections and vitamin D deficiency as potential risk factors for leprosy: A case-control study in south-eastern Brazil. 61
33592342 2021
50
Key sources of strength and resilience for persons receiving services for Hansen's disease (leprosy) in Porto Velho, Brazil: What can we learn for service development? 61
33547894 2021

Variations for Hansen's Disease

Expression for Hansen's Disease

Search GEO for disease gene expression data for Hansen's Disease.

Pathways for Hansen's Disease

GO Terms for Hansen's Disease

Sources for Hansen's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....